Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: Are we closer to knowing who needs it?

Lazaros Lekakis, Brenda W. Cooper, Marcos G. De Lima

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Acute myeloid leukemia (AML) is a very heterogeneous disease. Prognosis is related not only to intrinsic characteristics such as cytogenetics and molecular markers, but also the patient's ability to tolerate therapy, and treatment response. Allogeneic stem cell transplantation (allo-HCT) has been traditionally indicated for poor-risk disease in first complete remission (CR1) or for treatment of relapsed or refractory AML. 'Poor-risk' disease is now better defined due to genetic subtyping, particularly in chromosomally normal AML. In addition, the presence of comorbid conditions should be included in the decision-making process. Improvements in supportive care and the use of modern conditioning regimens have been associated with improved outcomes, mostly due to a reduction in treatment-related mortality. Therefore, a significant proportion of patients with AML-CR1 can potentially benefit from allo-HCT. We give general guidelines on how to incorporate cytogenetic and molecular risk factors, donor selection, and patient characteristics in order to determine when allo-HCT should be indicated in CR1.

Original languageEnglish
Pages (from-to)128-137
Number of pages10
JournalCurrent Hematologic Malignancy Reports
Volume9
Issue number2
DOIs
StatePublished - Jan 1 2014

Fingerprint

Stem Cell Transplantation
Acute Myeloid Leukemia
Cytogenetics
Donor Selection
Aptitude
Therapeutics
Decision Making
Guidelines
Mortality

Keywords

  • Acute myelogenous leukemia
  • Remission
  • Stem cells
  • Transplant

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission : Are we closer to knowing who needs it? / Lekakis, Lazaros; Cooper, Brenda W.; De Lima, Marcos G.

In: Current Hematologic Malignancy Reports, Vol. 9, No. 2, 01.01.2014, p. 128-137.

Research output: Contribution to journalArticle

@article{7458c5e4cd754e6391ce3b6d67246ade,
title = "Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: Are we closer to knowing who needs it?",
abstract = "Acute myeloid leukemia (AML) is a very heterogeneous disease. Prognosis is related not only to intrinsic characteristics such as cytogenetics and molecular markers, but also the patient's ability to tolerate therapy, and treatment response. Allogeneic stem cell transplantation (allo-HCT) has been traditionally indicated for poor-risk disease in first complete remission (CR1) or for treatment of relapsed or refractory AML. 'Poor-risk' disease is now better defined due to genetic subtyping, particularly in chromosomally normal AML. In addition, the presence of comorbid conditions should be included in the decision-making process. Improvements in supportive care and the use of modern conditioning regimens have been associated with improved outcomes, mostly due to a reduction in treatment-related mortality. Therefore, a significant proportion of patients with AML-CR1 can potentially benefit from allo-HCT. We give general guidelines on how to incorporate cytogenetic and molecular risk factors, donor selection, and patient characteristics in order to determine when allo-HCT should be indicated in CR1.",
keywords = "Acute myelogenous leukemia, Remission, Stem cells, Transplant",
author = "Lazaros Lekakis and Cooper, {Brenda W.} and {De Lima}, {Marcos G.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s11899-014-0207-4",
language = "English",
volume = "9",
pages = "128--137",
journal = "Current Hematologic Malignancy Reports",
issn = "1558-8211",
publisher = "Springer Science + Business Media",
number = "2",

}

TY - JOUR

T1 - Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission

T2 - Are we closer to knowing who needs it?

AU - Lekakis, Lazaros

AU - Cooper, Brenda W.

AU - De Lima, Marcos G.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Acute myeloid leukemia (AML) is a very heterogeneous disease. Prognosis is related not only to intrinsic characteristics such as cytogenetics and molecular markers, but also the patient's ability to tolerate therapy, and treatment response. Allogeneic stem cell transplantation (allo-HCT) has been traditionally indicated for poor-risk disease in first complete remission (CR1) or for treatment of relapsed or refractory AML. 'Poor-risk' disease is now better defined due to genetic subtyping, particularly in chromosomally normal AML. In addition, the presence of comorbid conditions should be included in the decision-making process. Improvements in supportive care and the use of modern conditioning regimens have been associated with improved outcomes, mostly due to a reduction in treatment-related mortality. Therefore, a significant proportion of patients with AML-CR1 can potentially benefit from allo-HCT. We give general guidelines on how to incorporate cytogenetic and molecular risk factors, donor selection, and patient characteristics in order to determine when allo-HCT should be indicated in CR1.

AB - Acute myeloid leukemia (AML) is a very heterogeneous disease. Prognosis is related not only to intrinsic characteristics such as cytogenetics and molecular markers, but also the patient's ability to tolerate therapy, and treatment response. Allogeneic stem cell transplantation (allo-HCT) has been traditionally indicated for poor-risk disease in first complete remission (CR1) or for treatment of relapsed or refractory AML. 'Poor-risk' disease is now better defined due to genetic subtyping, particularly in chromosomally normal AML. In addition, the presence of comorbid conditions should be included in the decision-making process. Improvements in supportive care and the use of modern conditioning regimens have been associated with improved outcomes, mostly due to a reduction in treatment-related mortality. Therefore, a significant proportion of patients with AML-CR1 can potentially benefit from allo-HCT. We give general guidelines on how to incorporate cytogenetic and molecular risk factors, donor selection, and patient characteristics in order to determine when allo-HCT should be indicated in CR1.

KW - Acute myelogenous leukemia

KW - Remission

KW - Stem cells

KW - Transplant

UR - http://www.scopus.com/inward/record.url?scp=84903613935&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903613935&partnerID=8YFLogxK

U2 - 10.1007/s11899-014-0207-4

DO - 10.1007/s11899-014-0207-4

M3 - Article

C2 - 24664820

AN - SCOPUS:84903613935

VL - 9

SP - 128

EP - 137

JO - Current Hematologic Malignancy Reports

JF - Current Hematologic Malignancy Reports

SN - 1558-8211

IS - 2

ER -